FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis — NEJM

FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis — NEJM

瀏覽:1257
日期:2024-07-13
Citing Articles 1 Harvey Rubin, Trevor Selwood, Takahiro Yano, Damian G. Weaver, H. Marie Loughran, Michael J. Costanzo, Richard W. Scott, Jay E. Wrobel, Katie B. Freeman, Allen B. Reitz. (2014) Acinetobacter baumannii OxPhos inhibitors as selective anti ...看更多